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a b s t r a c t
The Cyberknife represents a new, frameless stereotactic radiosurgery system which efﬁ-
ciently incorporates advance robotics with computerized image reconstruction to allow
highly conformal image guided radiation delivery. This review focus is on the pros and cons
of this new radiotherapy tool, its current indications, safety proﬁle and future directions.
A literature search of Medline, Pubmed, Biomed, Medscape and Cancer lit database were
referred to retrieve relevant data/information. The authors conclude that the use of this
system offers an invaluable solution to the treatment of selective tumours/lesions located
close to critical structures, salvage of recurrent andmetastatic lesions and potential of treat-tereotactic radiosurgery
obotics
ment of selective early stage malignancies like the carcinoma prostate and lung. However,
it is still too premature, with insufﬁcient follow up data to advocate it as the treatment of
here
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1. Introduction
Stereotactic body radiation therapy (SBRT) utilizes a novel 3D
co-ordinate system with advanced image enhancement and
fusion to permit a highly conformal and accurate radiotherapy
plan. Stereotactic body radiation therapy has the advantage
over standard conformal radiotherapy in requiring very min-
imal margins for setup uncertainty allowing for maximal
sparing of normal tissues. The dose volume sparing advantage
of SBRT makes it an ideal tool for delivering hypofraction-
ated radiotherapy.With SBRT, discrete lesions are treatedwith
radiobiologically higher doses with the goal of maximizing
local control.
In this aspect it has the advantage over surgery in requiring
lesser margins than safely required with a surgical resection,1
the radiobiological beneﬁts of tumour control, as the predicted
risk of normal tissue complications is still not understood and
more clinical studieswith longer followupwould better deﬁne
these variables.1–5
2. Radiobiology of SBRT
2.1. Double impact
Potential beneﬁts of hypofractionation: the use of large frac-
tion sizes, greater than 8Gy, may be more advantageous than
conventional fractionation in achieving complete elimina-
tion of tumour clonogens with a short continuous schedule,
reducing the risks of tumour repopulation.6,7 However, on the
negative side, this aspect of damage also holds true for nor-
mal tissue which may not be totally spared in spite of a highly
conformal treatment volume. This heightens the concern over
late toxicity.8,9
2.2. Mechanism of radiobiological damage
Evidence has been obtained that large radiation doses induce
endothelial cell damage causing microvascular dysfunction
enhancing the killing of tumour cells. The instigation of apop-
tosis for these cells triggers translocation of endothelial cell
acid spingomylinase into the plasma membrane where it is
hydrolyzed to sphingomyelin.10 This results in the generation
of ceramide, which acts as a second messenger for apoptosis.
The radiobiological effectiveness of a plan is usually pre-
dicted by the Linear Quadratic model. The validity of this
model to quantify the risk of late effects has been questioned
as it has been derived from data acquired through in vitro cell
survival assay of cancer cell lines. Therefore, this tool may
overestimate the potential for cell kill, andmayunderestimate
the in vivo risk of toxicity. Nonetheless, there is growing evi-
dence that tumours with low alpha/beta value may actually
achieve superior biological equivalent dosewith hypofraction-
ation and patients aremaximally beneﬁtted by this treatment.
Carcinoma prostate and other slowly proliferating tumours
such as chordomas, chondrosarcomas, meningiomas, acous-
tic neuroma, etc. all fall into this category. The converse is
however also true regarding normal tissues which also have
lower alpha/beta ratio and may manifest injury if they receive
high dose per fraction.11,12diotherapy 1 5 ( 2 0 1 0 ) 93–97
2.3. Greyzones
There are a few theoretical downsides that have to be further
evaluated. The use of a small number of fractions with-
out a gap prevents the tumour cells from reasserting into
more sensitive phases of its cycle.13,14 The same apply to
re-oxygenation, a potential radio sensitizing effect of fraction-
ated treatment.
2.4. Technical aspects of SBRT
Stereotactic body radiotherapy uses a 3-dimensional co-
ordinate system utilizing internal ﬁducials or image guidance
for tumour tracking and treatment delivery. Cyberknife has
the advantage over other SBRT systems in that it is capable
of tracking the co-ordinates in real time while the head of
the accelerator re-aligns itself to accommodate ﬂuctuations in
target position. The delivery of SBRT generally utilizes multi-
ple noncoplanar arcing ﬁelds directed at the radiation target.
As a result, the dose gradient is much deeper than conven-
tional radiation and irregularly shaped. The dose with SBRT
is generally prescribed to the isodose line encompassing the
target which allows for an inhomogenous dose delivery in
which the core of the target receives a much higher dose.
This may be especially advantageous when anticipating a
hypoxic core that may harbour resistant clonogens. Stereo-
tactic body radiation fractionation uses doses that may range
from 5 to 30Gy/fraction and often takes into consideration the
BED offered by dose escalation.
Stereotactic body radiotherapy is the best tool for sparing
parallel normal tissue, abutting planned large volumes. Even
several tissues like lung, liver and kidney may beneﬁt when
functional subunits aremaximally preserved by the deep dose
gradients.
3. Practical limitations
A few subgroups of patients with lesions otherwise best ben-
eﬁtted by this treatment may face difﬁculties associated with
stringent immobilization and long delivery times of more
than 40min. In pediatric patients it may often be difﬁcult
to reproduce adequate sedation and immobilization for such
extended periods. Elderly patients, and others with functional
or mechanical bladder instability, or patients with respi-
ratory compromise in the supine position may react with
restless movement beyond the machine’s correction param-
eter. Although emergency stops counter the situation, the
total treatment times may be overly extended. Some patients
with recurrent or metastatic lesions may not meet general
conditions amenable to invasive ﬁducial placement or might
be compromised by the time gap usually given to allow for
ﬁducial migration. Fiducial placement is integral to tumour
tracking for any extracranial site with anticipated movement
with respiration. Therefore, patients with sites not amenable
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.1. Indications for Cyberknife treatment and current
linical scenario
s of now themajority of Cyberknife treatmenthas beendeliv-
red to adult patients. Only 2 studies have reported its use
n children between 5 months and 16 years.15 The major-
ty of studies are also concentrated on palliative settings,
lthough currently increasing interest is being focused on
urative intent for early small volume disease, especially in
enign conditions, AV malformations, trigeminal neuralgia,
coustic neuroma, meningiomas and pituitary adenomas.
.2. Role of Cyberknife in speciﬁc sites – carcinoma
ung
tereotactic body radiation is commonly used to treat lung
ancer, both in a palliative setup of metastatic/recurrent
isease and curative treatment of early stage medically inop-
rable patients or those who refuse surgery.
Fractionation schedules used have varied from
Gy/fraction to 33Gy/fraction. Patients receiving doses
reater than 100Gy BED did signiﬁcantly better than those
eceiving less. Local progressionwas 3 times longer in patients
eceiving doses of more than 100Gy BED.16
Local control in patients receiving doses of more than
0Gy/fraction varied from 54 to 73% at 6 months. A dose
esponsive relation has been observed with local control
ncreasing to 90% with higher doses, however, it is associated
ith signiﬁcant toxicity. Radiation associated grade 3/4 tox-
city was observed nearly in 40% of patients receiving more
han 20Gy in any series. A signiﬁcant treatment mortality of
0% can also be expected. Unlike conformal radiation, pneu-
onitis has not been correlated with V20 and V13 equivalent.
ulmonary tolerance was also dependant on the type of prior
reatment received and current condition of the lung.17
Rib fractures also constitute a painful complication. No rib
ractures were observed when volume of the rib to chest wall
eceiving more than 30Gy in 3–5 sessions was less than 35ml.
racial plexopathy is another troublesome complication that
as been observed inmore than 65% cases. Of patients receiv-
ng biologically equivalent doses of more than 100Gy, late
hanges like consolidation and ﬁbrosis are inevitable at the
adiation site often compromising the evaluation of primary
esion on follow up. In spite of various limitations in treat-
ng lung lesions, Cyberknife does provide an equally effective
anagement for peripheral, medically inoperable stage 1 lung
esion. Several ongoing Phase II studies focus on its potential
n this setup. As of date, the use of SBRT in primary lung can-
er treatment is still protocol based and requires validation
n a cohort of good surgical risk patients to identify its actual
otential.
. Efﬁcacy in pancreatic tumours
adiation canplay an important role in palliation of pancreatic
arcinoma or even prophylactic palliation of local regression,
iliary obstruction, and splanchnic nerve pain. Stereotac-
ic body radiotherapy has the advantage of improved local
ontrol and is more patient friendly in terms of shorter treat-iotherapy 1 5 ( 2 0 1 0 ) 93–97 95
ment time, faster palliation and better normal tissue sparing.
Two Phase II studies by Aarhus University18 and Stanford
University19 show conﬂicting reports regarding toxicity. Sur-
prisingly, the Stanford protocol with single fraction treatment
(25Gy) has lesser toxicity than the Aarhus protocol of 45Gy
in 5 fractions. The disparity only highlights the multitude of
variables thatmay have to be taken into accountwhen design-
ing a stereotactic radiotherapy treatment protocol. Carcinoma
Pancreas Phase II studies suggest a dose escalation advantage
with doses of 25Gy achieving 85% local control vs. 66% for
20Gy and 70% for 15Gy.20
5. Role of Cyberknife in liver
Stereotactic body radiotherapy has been used widely for
treatment of limited metastatic diseases and hepatocellular
carcinoma, which otherwise do not qualify for alternative
modalities. However, the toxicity of radiotherapy at this site is
signiﬁcant. A number of Phase I and II studies have evaluated
the role of stereotactic body radiotherapy in liver metastasis.
Patients receiving doses in the range of 20–25Gy per fraction,
for 3 fractions did not evidence any considerable toxicity. How-
ever, dose escalation to 30Gy/fraction was associated with
signiﬁcant gastric and duodenal ulceration 3 months after
SBRT. At the Princess Margaret Hospital, 41 patients with pri-
mary hepatocellular carcinoma or intraphepatic biliary cancer
were treated in a Phase I dose escalation study (24–60Gy) in
6 fractions based on the effective liver volume to be irradi-
ated. Acute (3 months) elevation of enzymes occurred in 24%
of patients and acute biliary obstruction was observed in 5%
of patients and should be anticipated with stereotactic body
radiotherapy at this site. There was one death case following
gastrointestinal bleeding subsequent to duodenal ulceration
which may be considered as a dose limiting toxicity.
6. Role in treating lesions/tumours of the
spine
Nearly 9 studies21–25 have evaluated the role of Cyberknife
in spinal lesions. Conclusions are hard to derive as the sub-
jects are highly hetereogenous in the type of spinal lesions
involved (primary metastatic or benign). As a primary treat-
ment Cyberknife can achieve a local control of nearly 90%
in patients with a median follow up of 18 months. Radicular
pain has been relieved in 25–85% of patients and neurological
deﬁcits improved to a lesser degree. Several large studies have
analyzed the planning constraints in the treatment of spinal
lesions. They have inferred that a constraint of 10Gy to less
than 10% of contoured spinal cord is safe. Currently available
data suggest that a higher maximal dose of 20Gy is also safe
and feasible. This makes a very good option for patients with
previously irradiated spine and metastatic disease.
7. Other indicationsCyberknife has been tried in the management of intractable
trigeminal neuralgia.26–28 The neuralgia has been relieved in
20–90% of patients reviewed. Doses of 63.3–66Gy have been
nd ra
r96 reports of practical oncology a
used, however, with these doses failure is likely to occur in
3–29% of treated patients.
Cyberknife has been used in arteriovenous malformation
for patients who are not suitable for invasive surgery. Nearly
80% of patients treated will achieve a reduction in the malfor-
mation within 3 years.
Currently innovative experimental indications for radio-
surgery to treat functional disorders like obsessive compulsive
disorder (OCD), depression, parkinsonism, atrial ﬁbrillation,
etc. are underway. As beneﬁt in such situations require short
term follow up data, we should soon have evidence for a new
tool in themanagement of these usually refractory conditions.
8. Conclusion
8.1. Future directions
Cyberknife has already proved its role in effective palliation
with superior normal tissue sparing in a number of setups.
The next step would be to evaluate curative treatment of
small volume malignancies. To this end, larger studies are
now underway in carcinoma prostate and non-small cell lung
cancer. However, considering a selective nature of indications,
limited number and heterogeneity of treatment regimens,
Phase III trials/randomized trials are unlikely to materialize.
As of now, the best option for gathering such information
would be to pool in of multi-institutional data. These have to
be analyzed to receive an acceptable standard, of maximum
efﬁcacy and minimum toxicity of dose fractionation scheme.
Studies need to focus on potential long term expected and
unexpected side effects.
Current data, however, have validated thatwehave ahighly
efﬁcient radiotherapeutic modality for delivery of hypofrac-
tionated radiotherapy in a variety of clinical scenarios and
sites.
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